Tailored eradication


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
14 Dec 2019
Historique:
received: 27 09 2019
revised: 30 11 2019
accepted: 07 12 2019
entrez: 21 12 2019
pubmed: 21 12 2019
medline: 6 5 2020
Statut: ppublish

Résumé

Few studies have compared the efficacy and safety profile of a tailored eradication (TR) strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy (EBQT) for first-line eradication of To compare the efficacy and safety of a TR strategy and those of EBQT regimen as first-line eradication therapy for This is an open-label, comparative study in which we prospectively enrolled patients over 18 years of age with A total of 150 patients were assigned to the TR ( DPO-PCR-based TR for

Sections du résumé

BACKGROUND BACKGROUND
Few studies have compared the efficacy and safety profile of a tailored eradication (TR) strategy based on the presence of a 23S ribosomal RNA point mutation with those of empirical bismuth-based quadruple therapy (EBQT) for first-line eradication of
AIM OBJECTIVE
To compare the efficacy and safety of a TR strategy and those of EBQT regimen as first-line eradication therapy for
METHODS METHODS
This is an open-label, comparative study in which we prospectively enrolled patients over 18 years of age with
RESULTS RESULTS
A total of 150 patients were assigned to the TR (
CONCLUSION CONCLUSIONS
DPO-PCR-based TR for

Identifiants

pubmed: 31857776
doi: 10.3748/wjg.v25.i46.6743
pmc: PMC6920661
doi:

Substances chimiques

Antacids 0
Anti-Bacterial Agents 0
Proton Pump Inhibitors 0
RNA, Ribosomal, 23S 0
Metronidazole 140QMO216E
Amoxicillin 804826J2HU
Clarithromycin H1250JIK0A
Bismuth U015TT5I8H

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6743-6751

Informations de copyright

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Références

Int J Mol Sci. 2017 Aug 03;18(8):null
pubmed: 28771198
Am J Gastroenterol. 2014 Oct;109(10):1595-602
pubmed: 25091062
Jpn J Infect Dis. 2015;68(3):176-80
pubmed: 25672355
Helicobacter. 2019 Apr;24(2):e12561
pubmed: 30632237
J Gastrointestin Liver Dis. 2017 Sep;26(3):225-229
pubmed: 28922433
J Gastroenterol Hepatol. 2014;29(7):1371-86
pubmed: 24758240
Helicobacter. 2017 Aug;22(4):null
pubmed: 28425141
Helicobacter. 2019 Feb;24(1):e12546
pubmed: 30346636
Eur J Gastroenterol Hepatol. 2015 Mar;27(3):221-5
pubmed: 25629566
Helicobacter. 2019 Apr;24(2):e12565
pubmed: 30698318
PLoS One. 2017 Sep 28;12(9):e0183302
pubmed: 28957341
World J Gastroenterol. 2014 Jun 7;20(21):6547-53
pubmed: 24914376
Eur J Gastroenterol Hepatol. 2012 Apr;9 Suppl 1:S3-6; discussion S6-7
pubmed: 22498905
World J Gastroenterol. 2018 Oct 28;24(40):4548-4553
pubmed: 30386104
Microb Drug Resist. 2016 Apr;22(3):227-32
pubmed: 26618567
Gut. 2017 Jan;66(1):6-30
pubmed: 27707777
Helicobacter. 2018 Sep;23 Suppl 1:e12522
pubmed: 30203583
BMC Gastroenterol. 2011 Oct 17;11:112
pubmed: 22004003
Int J Med Sci. 2017 May 15;14(6):595-601
pubmed: 28638276
J Gastroenterol Hepatol. 2019 Apr;34(4):700-706
pubmed: 30011083
BMC Gastroenterol. 2016 Jul 26;16(1):79
pubmed: 27460100
Cancer Lett. 2014 Apr 10;345(2):196-202
pubmed: 23981572
Medicine (Baltimore). 2015 Nov;94(47):e2056
pubmed: 26632710
Helicobacter. 2016 Apr;21(2):91-9
pubmed: 26104022
Gastroenterology. 2016 May;150(5):1113-1124.e5
pubmed: 26836587
J Gastroenterol Hepatol. 2012 Nov;27(11):1675-80
pubmed: 22849546
Medicine (Baltimore). 2018 Aug;97(33):e11835
pubmed: 30113472
World J Gastroenterol. 2018 Jul 28;24(28):3071-3089
pubmed: 30065554
Gut Liver. 2018 Nov 15;12(6):641-647
pubmed: 30037168
Gut Liver. 2017 Sep 15;11(5):648-654
pubmed: 28750485

Auteurs

Youn I Choi (YI)

Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, South Korea.

Jun Won Chung (JW)

Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, South Korea. junwonchung@hanmail.net.

Dong Kyun Park (DK)

Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, South Korea.

Kyoung Oh Kim (KO)

Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, South Korea.

Kwang An Kwon (KA)

Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, South Korea.

Yoon Jae Kim (YJ)

Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon 21565, South Korea.

Ja Young Seo (JY)

Department of Laboratory Medicine, Gil Medical Center, Gachon University, Incheon 21565, South Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH